Why Aegerion Shares Popped

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biotechnology company Aegerion Pharmaceuticals (NASDAQ: AEGR  ) popped 10% today after the company's quarterly results and outlook topped Wall Street expectations.

So what: The stock has soared over the past year on the particularly strong launch of Juxtapid -- which treats a rare genetic disease called homozygous familial hypercholesterolemia, or HoFH -- and today's news only reinforces that blockbuster profit potential. In fact, management said that 215 patients are already on the drug right now, putting the company on a great pace to beat its goal of 250-300 patients at year's end.

Now what: Management now sees 2013 Juxtapid sales of $30 million-$35 million, up significantly from its prior view of $15 million-$25 million.

"We remain highly focused on delivering lomitapide to HoFH patients globally, and our regulatory progress continues with ongoing filings for approval in key markets," CEO Marc Beer said. "With this planned global expansion, we are building the foundation for long-term growth."

Of course, with the stock now up a whopping 450% over the past year, Fools will need plenty of biotech savvy to estimate just how much of that growth is already baked into the valuation.      

It's no secret that biotech stocks like Aegerion have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2566910, ~/Articles/ArticleHandler.aspx, 9/27/2016 3:15:55 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,220.43 125.60 0.69%
S&P 500 2,159.14 13.04 0.61%
NASD 5,302.03 44.54 0.85%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 2:59 PM
AEGR $2.77 Up +0.12 +4.53%
Aegerion Pharmaceu… CAPS Rating: **